Shares of drugmaker Bristol-Myers Squibb (NYSE:BMY) have rocketed upward since the start of 2013, trouncing the S&P 500 and many of its big pharma peers after reporting positive clinical trial data earlier this year. That doesn't mean, however, that Bristol no longer has room to grow. In the following video, taken from The Motley Fool's health care show, health care analysts David Williamson and Max Macaluso examine Bristol's biggest opportunities and some of the competitors it is currently facing.


David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.